The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Gilteritinib, venetoclax, low-dose cytarabine, and actinomycin D in FLT3-mutated AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses a retrospective single-center analysis of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) treated with gilteritinib, venetoclax, low-dose cytarabine, and actinomycin D as first salvage therapy. The study reported a 100% overall response rate (ORR) and an 88% complete remission (CR) plus complete remission with partial hematologic recovery (CRp) rate. Over two-thirds of patients were bridged to allogeneic stem cell transplantation (alloSCT), resulting in a median overall survival (OS) of 32 months. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
